Replies to post #304273 on Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

The previous IP holders did early antiviral testing. At the time, the push was for a new generation of antibacterial drugs against resistant strains. The focus (not IPIX/CTIX) became antibacterial development as the (at the time) low hanging fruit. So, there existed evidence of antiviral efficacy before CTIX bid and won the IP.

[slcimmuno]

Simply put—imo: once you really glob onto Defensins and their multiple MOAs (whatever the pathogen) it’s easy to see what they can do — that is to say when computationally designed to overcome the challenges that have plagued dev of the natural AMPs/HDPs... BRI has been delivering on the Promise whereas all the other attempts (Pexiganan, Omiganan) largely met with Peril, falling short of the PYMX Brain Trust to create our BRI-onic platform drug. Re that In Silico article - complex quantum docking of 11,000+ compounds spat out BRI as I think 3rd most promising to interfere w Mpro - main protease - replication... and this goes to the intracellular part of BRI likely MOA. BRI again, prior to infection, likely neutralizes and blocks, unlike most other antivirals. Anyway, based on recent share price action, The Sleeper has Awakened...